Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1990 3
1991 1
1992 1
1994 1
2001 3
2002 1
2006 2
2007 3
2011 3
2012 2
2013 5
2014 6
2015 5
2016 2
2017 5
2018 5
2019 11
2020 16
2021 13
2022 13
2023 14
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Dual-energy CT in pulmonary vascular disease.
Vlahos I, Jacobsen MC, Godoy MC, Stefanidis K, Layman RR. Vlahos I, et al. Among authors: layman rr. Br J Radiol. 2022 Jan 1;95(1129):20210699. doi: 10.1259/bjr.20210699. Epub 2021 Sep 24. Br J Radiol. 2022. PMID: 34538091 Free PMC article. Review.
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Mukohara T, et al. Among authors: layman rm. Nat Med. 2024 Aug;30(8):2242-2250. doi: 10.1038/s41591-024-03060-0. Epub 2024 Jun 1. Nat Med. 2024. PMID: 38824244 Free PMC article. Clinical Trial.
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Layman RM, et al. Lancet Oncol. 2024 Apr;25(4):474-487. doi: 10.1016/S1470-2045(24)00034-2. Lancet Oncol. 2024. PMID: 38547892 Clinical Trial.
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".
Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Lim B, et al. Among authors: layman r. Cell Rep Med. 2024 Jun 18;5(6):101595. doi: 10.1016/j.xcrm.2024.101595. Epub 2024 Jun 4. Cell Rep Med. 2024. PMID: 38838676 Free PMC article. Clinical Trial.
Quantification of liver fat: A comprehensive review.
Goceri E, Shah ZK, Layman R, Jiang X, Gurcan MN. Goceri E, et al. Among authors: layman r. Comput Biol Med. 2016 Apr 1;71:174-89. doi: 10.1016/j.compbiomed.2016.02.013. Epub 2016 Feb 27. Comput Biol Med. 2016. PMID: 26945465 Review.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. Yam C, et al. Among authors: layman rm. Breast Cancer Res Treat. 2023 Jun;199(3):457-469. doi: 10.1007/s10549-023-06929-9. Epub 2023 Apr 15. Breast Cancer Res Treat. 2023. PMID: 37061619 Clinical Trial.
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy.
Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Iwase T, et al. Among authors: layman rm. Clin Cancer Res. 2024 Jun 3;30(11):2424-2432. doi: 10.1158/1078-0432.CCR-23-2947. Clin Cancer Res. 2024. PMID: 38629963 Free PMC article. Clinical Trial.
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Provencher L, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA. Cescon DW, et al. Among authors: layman rm. Clin Cancer Res. 2024 Jan 17;30(2):334-343. doi: 10.1158/1078-0432.CCR-23-0133. Clin Cancer Res. 2024. PMID: 37992310 Free PMC article. Clinical Trial.
123 results